PME100589
Human MDR-1 Protein; hFc Tag
Size
£171.00
- SKU:
- PME100589
- Additional Names:
- ABC20;CD243;CLCS;GP170;MDR1;P-GP;PGY1
- Molecular Weight:
- The protein has a predicted molecular mass of 34.2 kDa after removal of the signal peptide.The apparent molecular mass of MDR-1-hFc is approximately 25-55 kDa due to glycosylation.
- Purity:
- The purity of the protein is greater than 95% as determined by SDS-PAGE and Coomassie blue staining.
- Storage Conditions:
- Store at -20[o]C to -80[o]C for 12 months in lyophilized form. After reconstitution; if not intended for use within a month; aliquot and store at -80[o]C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.
- Supplier:
- DIMA Biotechnology Ltd
- Formulation:
- Lyophilized from sterile PBS; pH 7.4. Normally 5 % - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution.
- Target:
- MDR-1
- MDR-1(Phe72-Arg113) (Lys213-Thr215) (Thr318-Gln330) (Gly960-Asp973) hFc(Glu99-Ala330):
- MDR-1(Phe72-Arg113) (Lys213-Thr215) (Thr318-Gln330) (Gly960-Asp973) hFc(Glu99-Ala330)
- Extra Details:
- The membrane-associated protein encoded by this gene is a member of the superfamily of ATP-binding cassette (ABC) transporters. ABC proteins transport various molecules across extra- and intra-cellular membranes. ABC genes are divided into seven distinct subfamilies (ABC1; MDR/TAP; MRP; ALD; OABP; GCN20; White). This protein is a member of the MDR/TAP subfamily. Members of the MDR/TAP subfamily are involved in multidrug resistance. The protein encoded by this gene is an ATP-dependent drug efflux pump for xenobiotic compounds with broad substrate specificity. It is responsible for decreased drug accumulation in multidrug-resistant cells and often mediates the development of resistance to anticancer drugs. This protein also functions as a transporter in the blood-brain barrier. Mutations in this gene are associated with colchicine resistance and Inflammatory bowel disease 13. Alternative splicing and the use of alternative promoters results in multiple transcript variants. [provided by RefSeq; Feb 2017]
- Shipping Conditions:
- Ambient